Chemomab Therapeutics Ltd. (CMMB)
NCM · Healthcare · Biotechnology
$2.58
-0.77%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$18.9M
Shares Outstanding
7.3M
Exchange
NCM
Currency
USD
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (1.8M) | (2.0M) | (1.9M) | (2.2M) |
| Net Income | (1.7M) | (1.9M) | (1.8M) | (2.2M) |
| Diluted EPS | $-0.32 | $-0.24 | $-0.24 | $-0.96 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (28.5M) | (25.5M) | (14.7M) | (9.6M) |
| Net Income | (27.6M) | (24.2M) | (13.9M) | (9.0M) |
| Diluted EPS | $-9.68 | $-8.24 | $-3.44 | $-1.44 |